Previous work has demonstrated that preventative AMPK activation (i.e., AMPK activator treatment at the start of dietary initiation of atherosclerosis) was associated with decreased levels of the circulating chemokine CCL2 (18, 30). This evidence concerns the gene CCL2 and atherosclerosis.